Health Condition 1: E282- Polycystic ovarian syndrome
Conditions
Interventions
Intervention1: metformin with Imeglimin and metformin with placebo: metformin 500 mg once daily
with Imeglimin 500 mg Once daily for 6 months for one group and metformin 500 mg once daily with plac
Sponsors
Riya Sharma self
Eligibility
Inclusion criteria
Inclusion criteria: -Polycystic ovarian syndrome diagnosed patient with BMI = 25 kg/m2 -Patients willing to give informed consent.
Exclusion criteria
Exclusion criteria: -History of allergic reactions attributed to compounds of similar chemical or biologic composition of metformin or imeglimin -Patients with history renal dysfunction (documented in biochemical test), acute / chronic metabolic acidosis, congestive cardiac failure needing drug treatment, lactic acidosis -Patients on drug known to have significant drug-drug interactions either metformin or imeglimin -Pregnant females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin resistance using insulin resistance parameters like C-peptide, Homeostatic Model Assessment for insulin resistance (HOMO-IR)Timepoint: Two years | — |
Secondary
| Measure | Time frame |
|---|---|
| - Hyperandrogenism using S.Testosterone - Inflammation using AGEs, MDA,CRP - ADRs in both arm using WHO-UMC Causality assessment scale - Quality of life of polycystic ovarian syndrome patients will be assessed using a questionnaire Timepoint: Two years | — |
Countries
India
Contacts
Public ContactDr Waseem Rizvi
Jawaharlal Nehru Medical College Aligarh Muslim University
Outcome results
None listed